A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Advanced Solid TumorsThe purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
Inclusion Criteria:
* Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
* Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
* Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
Exclusion Criteria:
* History of or with active interstitial lung disease or pulmonary fibrosis.
* Active, known, or suspected autoimmune disease.
* Serious uncontrolled medical disorders.
* New onset, non-catheter-associated venous thromboembolism within the past 6 months.
* Other protocol-defined Inclusion/Exclusion criteria apply.
Study Location
Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de MontréalMontréal, Quebec
Canada
Contact Study Team
Rahima Jamal, Site 0016
51489080008444Local Institution - 0017
Local Institution - 0017Toronto, Ontario
Canada
Contact Study Team
Site 0017
Centre Hospitalier de l'Université de Montréal
Centre Hospitalier de l'Université de MontréalMontreal, Quebec
Canada
Contact Study Team
Rahima Jamal, Site 0016
51489080008444Princess Margaret Cancer Centre
Princess Margaret Cancer CentreToronto, Ontario
Canada
Contact Study Team
Albiruni Abdul Razak, Site 0017
6479709845- Study Sponsored By
- Bristol-Myers Squibb
- Participants Required
- More Information
- Study ID:
NCT06544655